// App-Quantinova.ai

Filters

Biomarkers











Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease











Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























2187 Abstracts

Phase II Trial Of Medium-Dose VP-16, Cyclophosphamide and Total-Body Irradiation Conditioning Regimen Before Allogeneic Stem Cell Transplantation For Acute Lymphoblastic Leukemia In Adults

Tatsunori Goto - American Society of Hematology (ASH) , 2013

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Acute lymphoblastic leukemia

Cyclophosphamide

Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) In Adults With Philadelphia Chromosome (Ph)-Negative Acute Lymphoblastic Leukemia (ALL): Results From The Group For Research On Adult ALL (GRAALL)

Nathalie Dhedin - American Society of Hematology (ASH) , 2013

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

Cyclophosphamide

Survival Improvements Following Myeloablative Allogeneic Hematopoietic Cell Transplantation For Acute Lymphoblastic Leukemia In Adolescents and Young Adults Have Been Comparable To Younger Children: A Study From The Cibmtr

William A. Wood - American Society of Hematology (ASH) , 2013

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Acute lymphoblastic leukemia

N/A

Deletions In TBL1XR1 Results In Glucocorticoid Resistance By Decreasing Glucocorticoid Signaling In Childhood B-Lymphoblastic Leukemia

Courtney L Jones - American Society of Hematology (ASH) , 2013

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

Glucocorticoid

Pre-BCR Signaling Activity Predicts Sensitivity To Syk Kinase Inhibition In B Cell Acute Lymphoblastic Leukemia (B-ALL)

Stefan Koehrer - American Society of Hematology (ASH) , 2013

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

PRT060318

Acute Lymphoblastic Leukemia (ALL) With Low-Hypodiploid/Near-Triploid Karyotype Is a Specific Clinical Entity Characterized By a High TP53 Mutation Frequency

Verena Patterer - American Society of Hematology (ASH) , 2013

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

TP53

Inherited GATA3 genetic Variants Are Associated With Childhood BCR-ABL1-Like Acute Lymphoblastic Leukemia and Increased Risk Of Relapse

Virginia Perez-Andreu - American Society of Hematology (ASH) , 2013

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

L-Tyrosine

Genome-Wide Association Analyses Identify Susceptibility Loci For Vincristine-Induced Peripheral Neuropathy In Children With Acute Lymphoblastic Leukemia

Barthelemy Diouf - American Society of Hematology (ASH) , 2013

Therapeutic Area

Disease

Drug/Treatment

Peripheral Nervous System

Acute lymphoblastic leukemia

Vincristine

A Phase I Study Of AC220 (Quizartinib) In Combination With Cytarabine and Etoposide In Relapsed/Refractory Childhood ALL and AML: A Therapeutic Advances In Childhood Leukemia & Lymphoma (TACL) Study

Todd M. Cooper - American Society of Hematology (ASH) , 2013

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

quizartinib

Ponatinib In Patients (pts) With Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Resistant Or Intolerant To Dasatinib Or Nilotinib, Or With The T315I BCR-ABL Mutation: 2-Year Follow-Up Of The PACE Trial

Jorge Cortes - American Society of Hematology (ASH) , 2013

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Acute lymphoblastic leukemia

Bosutinib

Minimal Residual Disease Levels At Time Of CR1 and Transplant Predict Outcome In Philadelphia Chromosome-Negative Adult ALL

Mingming Zhang - American Society of Hematology (ASH) , 2013

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

Vincristine

Disruption Of PML Nuclear Bodies Cooperates In The Pathogenesis Of Acute Promyelocytic Leukemia

Eva Moravcsik - American Society of Hematology (ASH) , 2013

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

Cysteine Hydrochloride

Using Genome Engineering To Prospectively Investigate The Pathogenesis Of MLL Translocations In Infant Acute Lymphoblastic Leukemia

Erin H. Breese - American Society of Hematology (ASH) , 2013

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

N/A

Characterization of lincRNA BALIR-6 in MLL rearranged B-lymphoblastic leukemia

Norma Iris Rodriguez-Malave - American Society of Hematology (ASH) , 2013

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

miR155

PU.1 and Spi-B Oppose Transformation Of Pre-B Cells Through Activation Of Key Genes Involved In B Cell Receptor Signalling

Darah A. Christie - American Society of Hematology (ASH) , 2013

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

Interleukin

RUNX1 Is Required For Maintenance Of Established T-ALL Blasts

Christopher R Jenkins - American Society of Hematology (ASH) , 2013

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

Aster

Epigenetic Dysregulation Of ZNF423 Impedes B-Cell Differentiation and Is Linked To Adverse Outcome Of Childhood B-Precursor ALL

Ann-Christin Puller - American Society of Hematology (ASH) , 2013

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

N/A

Leukemia Driven By a NUP98-Phd Domain Fusion Is Highly Sensitive To Disruption Of H3K4me3-Phd Domain Binding By a Small Molecule Inhibitor

Sheryl M Gough - American Society of Hematology (ASH) , 2013

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

Disulfiram

Pcft Is Silenced By DNA Methylation In Pediatric Acute Lymphoblastic Leukemia Resulting In Decreased Methotrexate Uptake

Calvin K. Lee - American Society of Hematology (ASH) , 2013

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

Decitabine

Loss Of Tumor Suppressor BTG1 Enhances ATF4 Function and Promotes Cell Survival

Laurens T. van der Meer - American Society of Hematology (ASH) , 2013

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

Asparaginase

Copyright © 2026. QuantiNova All rights reserved